Skip to main content
UploadLanguage (EN)Support
BusinessMobileSocial MediaMarketingTechnologyArt & PhotosCareerDesignEducationPresentations & Public SpeakingGovernment & NonprofitHealthcareInternetLawLeadership & ManagementAutomotiveEngineeringSoftwareRecruiting & HRRetailSalesServicesScienceSmall Business & EntrepreneurshipFoodEnvironmentEconomy & FinanceData & AnalyticsInvestor RelationsSportsSpiritualNews & PoliticsTravelSelf ImprovementReal EstateEntertainment & HumorHealth & MedicineDevices & HardwareLifestyle
Canadian Cancer Survivor Network, profile picture
Uploaded byCanadian Cancer Survivor Network
802 views

A pan-Canadian Pharmaceutical Alliance (pCPA) Update – Optimizing the Process for Patients

Please share this video with anyone who may be interested! Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR In this webinar: ● Update on the fast-evolving pCPA ● pCPA's impact on patient access to new, innovative treatments ● Thoughts from CCSN's Louise Binder on how pCPA can involve patients in the decision making process View the video: https://youtu.be/rd08iLHqKQM Follow our social media accounts: Twitter - https://twitter.com/survivornetca Facebook - https://www.facebook.com/CanadianSurvivorNet Pinterest - https://www.pinterest.com/survivornetwork YouTube - https://www.youtube.com/user/Survivornetca

Government & Nonprofit◦
Downloaded 18 times
A PAN-CANADIAN PHARMACEUTICALALLIANCE UPDATE – OPTIMIZING THE PROCESS FOR PATIENTS September 1, 2016
1. pCPA overview 2. Impact on patient access 3. How the pCPA process is evolving and what’s next for pCPA 4. How patients can engage What we will discuss 2
pCPA objectives • Increase access to clinically effective and cost-effective drug treatment options • Improve the consistency of drug funding decisions • Achieve consistent and lower drug costs • Reduce duplication and improve use of resources 3
pCPA participants Federal plans (NIHB etc.) • Includes all provinces / territories - QC joined in October 2015 • Federal plans joined in February 2016 4
Two streams: innovative and generics Innovative medicines Negotiate terms for product listing agreements (as of July 31 2016): • Closed / Completed: 112 • Underway: 32 • No negotiations: 38 • P/T negotiations: 13 Generic medicines Value Price Initiative caps 18 generic medicines at 18% of innovator and applies a tiered pricing framework for all other generic drugs Co-leads: ON & NS Co-leads: NS & SK 5
pCPA savings More than $712 million in savings annually July 2016 6 Price reductions for 18 generic drugs and negotiated price agreements for 95 brand name drugs (as of April 1, 2016)
pCPA process Existing meds • Therapeutic reviews • Renegotiations of existing PLAs etc. New meds CADTH recommendation pCPA deliberation No negotiations Individual consideration by plans Negotiations Letter of intent signed Jurisdictional listings 7
Proposed guiding principles for pCPA process • Holistic: consideration of value from multiple perspectives • Predictable: communication of process, timelines, participation, decision making • Consistent: consistent process & approach, recognizing unique nature of negotiations • Transparent: timely and regular public reporting • Efficient & Effective: reduce duplication and align with current national HTA review • Collaborative and representative: cross-jurisdictional engagement with stakeholders • Respectful: recognition of different perspectives and needs amongst stakeholders • Ethical: reflect ethical principles such as validity, veracity and autonomy • Value-driven: achieving value for the health care system 8
pCPA office • Established in September 2015 • Housed in the Ontario Public Drug Program • Office manager is Imran Ali • Working on developing negotiation guidelines Mandate: support national negotiations with manufacturers Tasks: • standardization of templates • multi-channel communications • administrative support and tracking of performance metrics • capacity building: additional expertise to support consistency of negotiations across jurisdictions, transparency of process and accountability 9
Impact on Patient Access: Trend to higher listing rates and more consistency 14 20 25 32 20 33 11 22 6 21 27 53 56 71 60 59 73 69 54 72 0 10 20 30 40 50 60 70 80 BC AB SK MB ON QC NB NS PE NL 2006 (out of 103 drugs) 2015 (out of 195 drugs) Source: IMS Brogan; PRA Quarterly; data represents the previous two years of listing decisions Number of New Medicines Added to Provincial Formularies (2006 vs. 2015) Percentage of new medicines reimbursed (2006 vs. 2015) 14% 19% 24% 31% 19% 31% 11% 21% 6% 20%14% 27% 29% 36% 31% 30% 37% 35% 28% 37% 0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50% BC AB SK MB ON QC NB NS PE NL 2006 2015 10
Total Provincial Gov’t Health Expenditures on Prescribed Medicines 2006-2013 (Actual) and 2014-2015 (Forecast), $ Billions Source: CIHI – National Health Expenditure Trends (C Series) $8.17 B $8.67 B $9.16 B $9.86 B $10.06 B $10.30 B $10.28 B $10.29 B $10.44 B $10.66 B $0 $2 $4 $6 $8 $10 $12 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 $Billions % of total health spending 8.5 % 8.4 % 8.2 % 8.3 % 8.0 % 7.9 % 7.6 % 7.5 % 7.3 % 7.4 % 11
pCPA process still evolving • Ongoing negotiation guidelines consultations • Timelines • Sorting/prioritization • Patient engagement • Biosimilars – new approaches • Class reviews and older products • Performance measures and evaluation of process • Updated approaches to generic drugs • Memorandum of Understanding across jurisdictions 12
Themes for discussion • Is there an increased role for patients at pCPA? • Policy and guideline development • Governance, leadership and accountability • Individual product input? • pCPA’s impact on cancer treatment access (e.g., new indications) • Transparency & accountability 13
William (Bill) Dempster wdempster@3sixtypublicaffairs.com 613.614.0283 (mobile) Johanne Chambers jchambers@3sixtypublicaffairs.com 613.799.3092 (mobile) Louise Binder louise.binder@rogers.com 416.457.3179 (mobile) 14